Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiOpticROCO:6850 +2.80%90 EV-to-EBIT is 50.08 as of Sep. 09, 2026, which is 83% above its 10-year median of 27.43. GuruFocus rates ROCO:6850 with a GF Score™ of 90/100 and a GF Value™ of NT$43.78 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 365 Biotechnology companies, BiOptic ranks worse than 81.37% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BiOptic's Enterprise Value is NT$996.1 Mil.
BiOptic's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$19.9 Mil. Therefore, BiOptic's EV-to-EBIT for today is 50.08.
The historical rank and industry rank for BiOptic's EV-to-EBIT or its related term are showing as below:
ROCO:6850'
s EV-to-EBIT Range Over the Past 10 Years
Min: 13.14 Med: 27.43 Max: 180.48
Current: 50.08
During the past 8 years, the highest EV-to-EBIT of BiOptic was 180.48. The lowest was 13.14. And the median was 27.43.
ROCO:6850's EV-to-EBIT is ranked worse than 81.37% of 365
companies
in the Biotechnology industry
Industry Median: 15.48
vs ROCO:6850: 50.08
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
BiOptic's Enterprise Value for the quarter that ended in Jun. 2026 was NT$1,029.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BiOptic's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$19.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiOptic EV-to-EBIT Related Terms
BiOptic EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for BiOptic's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6850 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, BiOptic's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiOptic EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiOptic's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BiOptic's EV-to-EBIT falls into.
BiOptic's current Enterprise Value is NT$996.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BiOptic's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$19.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiOptic (ROCO:6850) has a EV-to-EBIT of 50.08 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BiOptic and its competitors. This is 83% above median its historical median of 27.43. Over the past decade, BiOptic's EV-to-EBIT has ranged from 13.14 to 180.48. According to the industry distribution chart, BiOptic ranks #297 out of 365 companies in the Biotechnology industry, placing it in the top 81.4%.
Is BiOptic's EV-to-EBIT too high?
BiOptic's current EV-to-EBIT of 50.08 is 83% above median its 10-year median of 27.43. Over the past 10 years, this metric has ranged from a low of 13.14 to a high of 180.48. The Biotechnology industry median EV-to-EBIT is 15.48. BiOptic's value of 50.08 is 223.5% above this industry median. Based on the distribution chart, BiOptic ranks #297 out of 365 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BiOptic has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BiOptic's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BiOptic ranks #297 out of 365 companies for EV-to-EBIT. This places BiOptic in the lower half of its industry. The industry median EV-to-EBIT is 15.48. BiOptic's value of 50.08 is 223.5% above this benchmark. Historically, BiOptic's own EV-to-EBIT has ranged from 13.14 to 180.48 over the past decade. While the company's 10-year median is 27.43 vs. the industry median of 15.48, BiOptic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.48, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BiOptic's current EV-to-EBIT of 50.08 is 223.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BiOptic and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BiOptic's current EV-to-EBIT is 50.08, which is 83% above median its own 10-year median of 27.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BiOptic stock overvalued right now?
Based on GuruFocus' analysis, BiOptic (ROCO:6850) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$43.78, compared to a current price of NT$33.00 — trading 24.6% below its estimated fair value. The current EV-to-EBIT is 50.08, which is 83% above median its 10-year median of 27.43 and 223.5% above the Biotechnology industry median of 15.48. BiOptic's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BiOptic (ROCO:6850), the current EV-to-EBIT is 50.08 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BiOptic (ROCO:6850) Overvalued in 2026?
Based on GuruFocus' analysis, BiOptic stock appears to be undervalued.
The current stock price of NT$33.00 is trading 24.6% below its estimated GF Value™ of NT$43.78.
GuruFocus considers BiOptic to be Modestly Undervalued.
Key valuation signals for ROCO:6850:
EV-to-EBIT: 50.08 (83% above median its 10-year median of 27.43)
GF Value™: NT$43.78 vs. price of NT$33.00 (24.6% below fair value)
Industry Position: 223.5% above the Biotechnology median (#297 of 365)
No single metric tells the full story. See the ROCO:6850 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BiOptic Inc is a biotechnology instrumentation company that develops scientific products for research and clinical applications. It serves professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry, and agriculture, performing diagnostic molecular genetic analyses.
90GF Score
Get the complete analysis for ROCO:6850
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6850 has been successfully added to your 
